Loading organizations...
Key people at Actavis.
Actavis is a Dublin, Ireland and Parsippany, New Jersey-based global pharmaceutical company that develops, manufactures, and distributes generic, branded, and over-the-counter medical products, alongside operating an out-licensing business via Medis. Prior to its corporate restructuring, the enterprise generated over $13 billion in annual revenue, produced approximately 40 billion pharmaceutical units annually, and employed roughly 30,000 people across operations in more than 60 countries. The organization significantly expanded its global market presence through a 2012 merger with Watson Pharmaceuticals, followed by a $70.5 billion acquisition of Allergan, the manufacturer of Botox, before adopting the Allergan corporate name. Following this integration, the legacy Actavis global generics division was subsequently acquired by Teva Pharmaceuticals in a definitive transaction valued at $40.5 billion. The pharmaceutical company was originally founded in 1999 by Björgólfur Thor Björgólfsson, Björgólfur Guðmundsson, and Magnús Þorsteinsson.
Key people at Actavis.
Actavis, originally founded as Watson Pharmaceuticals in 1984 in Libertyville, Illinois, evolved into a global pharmaceutical giant specializing in branded and generic pharmaceuticals, over-the-counter medicines, and biologics, with operations in approximately 100 countries.[1][3][4] The company focused on developing, manufacturing, and marketing affordable high-quality alternatives to brand-name drugs, particularly in areas like central nervous system, gastroenterology, women's health, cardiovascular, oncology, and anti-infectives, achieving significant scale through acquisitions that propelled revenues past $1 billion by 2000 and positioned it as a top generics player.[1][2][5] It served patients, healthcare systems, and markets worldwide by increasing access to cost-effective treatments, but underwent major transformations: acquired by Allergan in 2015 (prompting a name change to Allergan plc) and later integrated into AbbVie.[1][4]
Actavis traces its roots to spring 1983, when Allen Chao, Ph.D., and David Hsia, Ph.D., launched a small drug development venture in Libertyville, Illinois, funded by friends and family; within two months, they established a six-employee lab focused on product development and analytics.[1][3] Initially operating as Watson Pharmaceuticals, it went public via NASDAQ IPO in 1993, moved to NYSE in 1997, and expanded aggressively: acquiring Schein Pharmaceutical in 2000 (doubling size and hitting $1B revenue), Andrx Corporation in 2006 (ranking it third in specialty pharma by prescriptions), and the Swiss Actavis Group in 2012 for €4.25 billion, adopting the Actavis name globally and becoming the third-largest generics firm.[1][3][5] Paul M. Bisaro succeeded Chao as CEO in 2007; the company reincorporated in Ireland as Actavis plc in 2013 to facilitate further growth.[1][6] Separate origins exist for regional arms, like PT Actavis Indonesia (starting as PT Dumex in 1969, acquired by Actavis in 2006).[2]
Actavis rode the wave of generics proliferation amid rising drug costs and patent cliffs, capitalizing on market forces like demand for affordable alternatives in a competitive landscape where big pharma faced innovation pressures.[5][8] Its timing was ideal post-2000s, as healthcare systems globally sought cost savings—evident in its rise to top-tier status via acquisitions amid consolidation in pharma.[1][3] The company influenced the ecosystem by democratizing access to treatments in high-need areas (e.g., CNS, oncology), boosting competition, and pioneering sustainable manufacturing, though its generics emphasis diverged from traditional R&D-heavy big pharma models.[2][4][5][8]
Post-2015 Allergan acquisition and AbbVie integration, Actavis as an independent entity ceased, but its legacy endures in AbbVie's generics and specialty portfolio, sustaining global access to affordable meds.[1][4] Trends like biosimilars growth, emerging markets expansion, and sustainability (e.g., green manufacturing) will shape its inherited impact, potentially amplifying influence in value-based healthcare amid ongoing patent expirations and cost pressures.[2][4][5] This trajectory from a small Illinois lab to pharma powerhouse underscores how acquisition-fueled scale can redefine industry access and efficiency.
